The Cancer Genomics Research (CGR) Laboratory was established to investigate the contribution of genetic variation to cancer susceptibility and outcomes. Working in concert with epidemiologists, biostatisticians and basic research scientists in the intramural research program, CGR developed the capacity to conduct genome-wide association studies (GWAS), candidate gene approaches, and next-generation sequencing applications to identify the heritable determinants of various forms of cancer. In addition to offering the latest in genomics technology, the CGR is a fully integrated and highly automated laboratory supporting several functional areas: DNA Extraction and Staging Laboratory (DESL) for preparation of samples; Laboratory Information Management System (LIMS) for advanced sample, project, and inventory tracking; comprehensive project management; production laboratory for high-throughput assays; quality assurance and control; research for focused research projects; functional research to follow-up interesting findings; HPV genomics research; technology development; quality assurance and control; and bioinformatics and scientific analysis capabilities, making it a unique collaborative center for NCI-driven scientific endeavors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research and Development Contracts (N01)
Project #
261200800001E-132-0-35
Application #
9665364
Study Section
Project Start
2008-09-26
Project End
2018-09-25
Budget Start
Budget End
Support Year
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Leidos Biomedical Research, Inc.
Department
Type
DUNS #
159990456
City
Frederick
State
MD
Country
United States
Zip Code
21702